Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Correspondence to: Terry Goldberg, PhD, Zucker Hillside Hospital, 7559 263rd Street, Glen Oaks, NY 11004, USA; firstname.lastname@example.org
Do the effects of olanzapine and risperidone on cognition in first-episode schizophrenia differ, and are the effects real or the result of repeating the tests?
104 people with DSM-IV first episode schizophrenia (76 with schizophrenia, 10 with schizoaffective disorder, and 18 with schizophreniform disorder) recruited through hospital-based research units who were all actively psychotic on enrolment; 84 healthy controls were recruited through newspaper advertisements and word of mouth. Exclusions: medical condition affecting the central nervous system, and having neurological conditions or taking drugs that affected cognition.
Hospitals in the USA; time period not stated.
People with first-episode schizophrenia (FES) were randomised to receive olanzapine (2.5–20 mg/d) or risperidone (1–6 mg/d) for 16 weeks. Healthy controls did not receive any medication.
Severity of illness (Schedule for Affective Disorders and Schizophrenia-Change Version; Schedule for the Assessment of Negative Symptoms); change in cognition (16 tests assessed domains including mental status, speed, executive function, memory and motor skills) all …
Source of funding: National Institutes of Health.
▸ Additional notes and a reference list are published online only at http://ebmh.bmj.com/content/vol11/issue2
Competing interests: None.